ned as the product-of-choice to address this need," said Peter Rule, chairman and chief executive officer of OptiScan Biomedical. "We look forward to continuing our development and regulatory efforts to secure approval and introduce the OptiScanner in Europe, the U.S. and other key countries. At the same time, we're focused on next-generation products that can bring even greater capabilities and benefits to physicians and patients in the ICU."
About OptiScan BiomedicalOptiScan Biomedical is a leading developer of innovative continuous glucose monitoring systems for use in intensive care units (ICU). The company's lead product is the OptiScanner™, a first-of-its-kind automated, bedside glucose monitoring system that provides highly accurate, continuous monitoring of patients' glucose levels measured in plasma, as opposed to whole blood. The system prominently displays glucose level trend data updated every 15 minutes to help manage patients' glucose levels within an optimum target range. OptiScan has received CE Mark certification for the OptiScanner in the European Union and is in active discussions with the United States Food and Drug Administration regarding approval of the product in the U.S.
The company is currently working to expand the capability of the OptiScanner platform technology by detecting additional analytes within the same blood sample, thereby providing additional information about the condition of a critically ill patient.
For more information visit: www.optiscancorp.comContact:OptiScan BiomedicalVida Communication (On behalf of OptiScan)Patrick Nugent, Chief Financial Officer
Tim Brons (media)510-342-5803
Page: 1 2 3 4 Related biology technology :1
|SOURCE OptiScan Biomedical Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research2
. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City3
. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors4
. 22 of Americas Most Promising Scientists Selected as 2011 Pew Scholars in the Biomedical Sciences5
. The Pittsburgh Life Sciences Greenhouse Announces Innovative Partnership With University of Pittsburgh Biomedical Engineering Society6
. Pennington Biomedical Research Center Study Suggests Decreases in U. S. Occupation Energy Levels a Significant Trigger of Obesity Epidemic7
. Saladax Biomedical, Inc. Announces European Commercialization Team8
. USC and Coulter Foundation Partner to Invest $5M in Breakthrough Innovation in Biomedical Engineering9
. Investing in Biomedical Innovation10
. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report11
. Californias Biomedical Industry is Poised for Growth Despite Increasing Global Competition, According to the 2011 California Biomedical Industry Report